SCHEMBL6432550

SCHEMBL6432550

COc1ccc(C(=NN)c2nc3nonc3nc2Nc2ccc(F)c(Cl)c2)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.42
EGFR P00533 7/20 0.38
MAPT P10636 6/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
ERBB2 P04626 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ACP1 P24666 1/20 0.36
TDO2 P48775 1/20 0.36
TP53 P04637 1/20 0.36
CCR2 P41597 1/20 0.36
CCR5 P51681 1/20 0.36
PNLIP P16233 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417864 0.94 APP (0.42) APPEGFRMAPTSMN1; SMN2HTT
SCHEMBL6432241 0.92 SMN1; SMN2 (0.38) MAPTSMN1; SMN2HTTRAB9AKDM4E
SCHEMBL6414240 0.90 MAPT (0.37) EGFRMAPTSMN1; SMN2HTTERBB2
SCHEMBL6414239 0.90 MAPT (0.37) EGFRMAPTSMN1; SMN2HTTERBB2
SCHEMBL6438171 0.88 TLR4 (0.41) EGFRMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6436126 0.88 FADS1 (0.43) EGFRMAPTSMN1; SMN2HTTNPC1
SCHEMBL6417043 0.86 SMN1; SMN2 (0.38) MAPTSMN1; SMN2HTTTP53CCR2
SCHEMBL6419775 0.86 MAPT (0.39) EGFRMAPTSMN1; SMN2HTTERBB2
SCHEMBL6419767 0.86 MAPT (0.39) EGFRMAPTSMN1; SMN2HTTERBB2
SCHEMBL6431540 0.85 AKR1C3 (0.38) EGFRMAPTSMN1; SMN2HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 APP 2245/4885EGFR 1083/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.